• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by BioXcel Therapeutics Inc.

    10/1/25 4:15:17 PM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BTAI alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    BioXcel Therapeutics, Inc.

    (Name of Issuer)


    Common Stock, par value $0.001 per share

    (Title of Class of Securities)


    09075P204

    (CUSIP Number)


    09/29/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    09075P204


    1Names of Reporting Persons

    Integrated Core Strategies (US) LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,026,054.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,026,054.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,026,054.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.2 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    09075P204


    1Names of Reporting Persons

    Millennium Management LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,028,053.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,028,053.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,028,053.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.2 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    09075P204


    1Names of Reporting Persons

    Millennium Group Management LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,028,053.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,028,053.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,028,053.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.2 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    09075P204


    1Names of Reporting Persons

    Israel A. Englander
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,028,053.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,028,053.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,028,053.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.2 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    BioXcel Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    555 Long Wharf Drive, New Haven, Connecticut 06511
    Item 2. 
    (a)Name of person filing:

    Integrated Core Strategies (US) LLC Millennium Management LLC Millennium Group Management LLC Israel A. Englander
    (b)Address or principal business office or, if none, residence:

    Integrated Core Strategies (US) LLC c/o Millennium Management LLC 399 Park Avenue New York, New York 10022 Millennium Management LLC 399 Park Avenue New York, New York 10022 Millennium Group Management LLC 399 Park Avenue New York, New York 10022 Israel A. Englander c/o Millennium Management LLC 399 Park Avenue New York, New York 10022
    (c)Citizenship:

    Integrated Core Strategies (US) LLC - Delaware Millennium Management LLC - Delaware Millennium Group Management LLC - Delaware Israel A. Englander - United States
    (d)Title of class of securities:

    Common Stock, par value $0.001 per share
    (e)CUSIP No.:

    09075P204
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See response to Item 9 on each cover page.
    (b)Percent of class:

    See response to Item 11 on each cover page.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See response to Item 5 on each cover page.

     (ii) Shared power to vote or to direct the vote:

    See response to Item 6 on each cover page.

     (iii) Sole power to dispose or to direct the disposition of:

    See response to Item 7 on each cover page.

     (iv) Shared power to dispose or to direct the disposition of:

    See response to Item 8 on each cover page. The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    See Exhibit I
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Integrated Core Strategies (US) LLC
     
    Signature:/s/ Gil Raviv
    Name/Title:Gil Raviv, Global General Counsel
    Date:09/30/2025
     
    Millennium Management LLC
     
    Signature:/s/ Gil Raviv
    Name/Title:Gil Raviv, Global General Counsel
    Date:09/30/2025
     
    Millennium Group Management LLC
     
    Signature:/s/ Gil Raviv
    Name/Title:Gil Raviv, Global General Counsel
    Date:09/30/2025
     
    Israel A. Englander
     
    Signature:/s/ Israel A. Englander
    Name/Title:Israel A. Englander
    Date:09/30/2025

    Comments accompanying signature:  ** INTEGRATED CORE STRATEGIES (US) LLC By: Integrated Holding Group LP, its Managing Member By: Millennium Management LLC, its General Partner
    Exhibit Information

    Exhibit I: Joint Filing Agreement, dated as of September 30, 2025, by and among Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.

    Get the next $BTAI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BTAI

    DatePrice TargetRatingAnalyst
    2/21/2024$9.00 → $4.00Buy → Neutral
    UBS
    8/15/2023$40.00 → $4.00Buy → Neutral
    Mizuho
    7/17/2023Buy → Neutral
    Guggenheim
    3/10/2023$20.00 → $22.00Buy → Hold
    Jefferies
    12/1/2022$16.00Sell → Neutral
    Goldman
    7/7/2022$19.00Buy
    Mizuho
    4/6/2022$80.00Buy
    BofA Securities
    2/16/2022$88.00 → $25.00Buy
    UBS
    More analyst ratings

    $BTAI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements

    NEW HAVEN, Conn., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that it has received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with the market value of listed securities ("MVLS") requirement under Nasdaq Listing Rule 5550(b)(2) (the "MVLS Rule"). As previously disclosed, on March 20, 2025, the Company was notified by Nasdaq that it was not in compliance with Nasdaq Listing Rule 5550(b)(2) because its MVLS was below $35.0 million for

    9/18/25 7:00:00 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia

    BXCL501 demonstrated a significant mean reduction in mCGI-S score from baseline compared to placebo at 2 hours across 2,433 treated episodes (p<.05) Complete resolution of agitation was significantly higher with BXCL501 compared to placebo across agitation episode severity (p<.0001) BXCL501 showed a similar reduction in agitation symptoms over both the duration of the trial and number of treated episodes, demonstrating continued effects and consistent benefit with repeat dosing of BXCL501 Based on the large body of evidence and positive FDA feedback, Company plans to submit a sNDA in Q1 2026 for expanded usage of IGALMI® in the outpatient setting Company to host virtual KOL call with Dr.

    9/10/25 6:30:00 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioXcel Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

    NEW HAVEN, Conn., Sept. 04, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics, will present a company overview at the H.C. Wainwright 27th Annual Global Investment Conference to be held September 8 - 10, 2025. Date: Monday, September 8, 2025Time: 4:30 p.m. Eastern TimeWebcast Link: HERE The live and archived webcast will also be available on the Events & Presentations page in the investors section of the Company's website. About BioXcel Therapeutics, Inc.BioXcel Therapeutics, Inc. (NASDAQ:

    9/4/25 7:00:00 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BTAI
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by BioXcel Therapeutics Inc.

    SCHEDULE 13G - BioXcel Therapeutics, Inc. (0001720893) (Subject)

    10/1/25 4:15:17 PM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioXcel Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events

    8-K - BioXcel Therapeutics, Inc. (0001720893) (Filer)

    9/15/25 8:30:41 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioXcel Therapeutics Inc. filed SEC Form 8-K: Other Events

    8-K - BioXcel Therapeutics, Inc. (0001720893) (Filer)

    9/10/25 6:30:40 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BTAI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for IGALMI issued to BIOXCEL THERAPEUTICS, INC.

    Submission status for BIOXCEL THERAPEUTICS, INC.'s drug IGALMI (ORIG-1) with active ingredient DEXMEDETOMIDINE has changed to 'Approval' on 04/05/2022. Application Category: NDA, Application Number: 215390, Application Classification: Type 3 - New Dosage Form

    4/6/22 2:18:32 PM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BTAI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $BTAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    BioXcel Therapeutics downgraded by UBS with a new price target

    UBS downgraded BioXcel Therapeutics from Buy to Neutral and set a new price target of $4.00 from $9.00 previously

    2/21/24 8:16:51 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioXcel Therapeutics downgraded by Mizuho with a new price target

    Mizuho downgraded BioXcel Therapeutics from Buy to Neutral and set a new price target of $4.00 from $40.00 previously

    8/15/23 7:17:23 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioXcel Therapeutics downgraded by Guggenheim

    Guggenheim downgraded BioXcel Therapeutics from Buy to Neutral

    7/17/23 7:16:08 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Mack David J. converted options into 1,694 shares, increasing direct ownership by 10% to 18,623 units (SEC Form 4)

    4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)

    10/1/25 7:00:03 PM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO and President Mehta Vimal converted options into 382 shares, increasing direct ownership by 2% to 20,493 units (SEC Form 4)

    4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)

    9/16/25 7:05:59 PM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Steinhart Richard I converted options into 68 shares, increasing direct ownership by 1% to 6,509 units (SEC Form 4)

    4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)

    9/16/25 7:04:35 PM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BTAI
    Leadership Updates

    Live Leadership Updates

    View All

    BioXcel Therapeutics Strengthens Clinical Development Leadership to Advance Late-Stage Programs

    Vincent J. O'Neill, M.D., promoted to Executive Vice President, Chief of Product Development and Medical Officer   Rajiv Patni, M.D., appointed Strategic Clinical Advisor to CEO and Board of Directors NEW HAVEN, Conn., Dec. 11, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced a key executive promotion and a clinical advisor appointment as part of the Company's strategic reprioritization focused on the advancement of its late-stage clinical programs and emerging pipeline candidates. Vincent J. O'Neill, M.D., Senior Vice

    12/11/23 7:00:00 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioXcel Therapeutics Appoints Michael P. Miller to Board of Directors

    NEW HAVEN, Conn., July 05, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced the appointment of Michael P. Miller to its Board of Directors, effective July 1, 2022. Mr. Miller brings nearly 40 years of strategic leadership and commercial growth experience in the pharmaceutical industry, where he most recently served as Executive Vice President, U.S. Commercial at Jazz Pharmaceuticals. "We are pleased to welcome Mike to our Board and believe his deep commercial and market access expertise will be

    7/5/22 7:00:00 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioXcel Therapeutics Appoints Matt Wiley Chief Commercial Officer

    NEW HAVEN, Conn., Jan. 19, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced the appointment of Matt Wiley as Senior Vice President and Chief Commercial Officer (CCO). "We are pleased to welcome Matt to our management team, as we prepare for our first potential approval and commercial launch of BXCL501 for the acute treatment of agitation associated with schizophrenia and bipolar disorders," said Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics. "With over 25 years of commercial and industry exper

    1/19/22 7:00:00 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BTAI
    Financials

    Live finance-specific insights

    View All

    UPDATE -- BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®

    BXCL501 achieved SERENITY At-Home's primary endpoint of being well tolerated in the at-home treatment of agitation episodes in patients with bipolar disorders or schizophrenia No discontinuations for tolerability in the BXCL501 arm While not the primary objective of the SERENITY At-Home trial, the preliminary results demonstrate continued effects and consistent benefit with repeat dosing across the course of the trial Following previously disclosed positive FDA feedback, BioXcel plans to submit a sNDA in Q1 2026 for expanded usage of BXCL501 in the outpatient setting without the supervision of a healthcare provider More than 2400 episodes of agitation were treated in the SERENITY At-Home

    8/27/25 8:00:16 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®

    BXCL501 achieved SERENITY At-Home's primary endpoint of being well tolerated in the at-home treatment of agitation episodes in patients with bipolar disorders or schizophrenia No discontinuations for tolerability in the BXCL501 arm While not the primary objective of the SERENITY At-Home trial, the preliminary results demonstrate continued effects and consistent benefit with repeat dosing across the course of the trial Following previously disclosed positive FDA feedback, BioXcel plans to submit a sNDA in Q1 2026 for expanded usage of BXCL501 in the outpatient setting without the supervision of a healthcare provider More than 2400 episodes of agitation were treated in the SERENITY

    8/27/25 7:00:00 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024

    Enrollment exceeds 60% of required number of patients in SERENITY At-Home pivotal Phase 3 safety trial evaluating 200 patients for acute treatment of agitation associated with bipolar disorders or schizophrenia Topline data expected in second half of 2025 intended to support potential sNDA submission for label expansion of IGALMI® in the at-home setting Strengthened cash position to advance BXCL501 program NEW HAVEN, Conn., March 27, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today reported its financial results for the fourth quarter and full year 2

    3/27/25 7:00:00 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BTAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by BioXcel Therapeutics Inc.

    SC 13G/A - BioXcel Therapeutics, Inc. (0001720893) (Subject)

    9/10/24 10:47:52 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by BioXcel Therapeutics Inc. (Amendment)

    SC 13D/A - BioXcel Therapeutics, Inc. (0001720893) (Subject)

    6/6/24 8:29:42 PM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by BioXcel Therapeutics Inc. (Amendment)

    SC 13G/A - BioXcel Therapeutics, Inc. (0001720893) (Subject)

    2/9/24 8:35:57 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care